Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) Gross Profit: 2021-2025

Historic Gross Profit for Oncology Institute (TOI) over the last 5 years, with Q3 2025 value amounting to $18.9 million.

  • Oncology Institute's Gross Profit rose 3169.98% to $18.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $312.1 million, marking a year-over-year increase of 10942.12%. This contributed to the annual value of $206.5 million for FY2024, which is 4420.41% up from last year.
  • Latest data reveals that Oncology Institute reported Gross Profit of $18.9 million as of Q3 2025, which was up 3169.98% from $68.7 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Gross Profit registered a high of $167.2 million during Q4 2024, and its lowest value of $14.4 million during Q3 2024.
  • Its 5-year average for Gross Profit is $41.5 million, with a median of $33.0 million in 2022.
  • Examining YoY changes over the last 5 years, Oncology Institute's Gross Profit showed a top increase of 34669.46% in 2024 and a maximum decrease of 6125.05% in 2024.
  • Over the past 5 years, Oncology Institute's Gross Profit (Quarter) stood at $25.0 million in 2021, then surged by 32.41% to $33.0 million in 2022, then rose by 13.26% to $37.4 million in 2023, then soared by 346.69% to $167.2 million in 2024, then tumbled by 88.68% to $18.9 million in 2025.
  • Its last three reported values are $18.9 million in Q3 2025, $68.7 million for Q2 2025, and $57.3 million during Q1 2025.